- Open Access
Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster model
© Nieto et al; licensee BioMed Central Ltd. 2011
- Received: 27 September 2010
- Accepted: 23 February 2011
- Published: 23 February 2011
Several animal models have been established to study visceral leishmaniosis (VL), a worldwide vector-borne disease affecting humans and domestic animals that constitutes a serious public health problem. BALB/c mice and Syrian hamsters are the most widely used experimental models. In this paper, we summarize the advantages and disadvantages of these two experimental models and discuss the results obtained using these models in different studies of VL. Studies using the BALB/c mouse model have underscored differences between the liver and spleen in the course of VL, indicating that pathological evaluation of the visceral organs is essential for understanding the immune mechanisms induced by Leishmania infantum infection. The main goal of this review is to collate the relevant literature on Leishmania pathogenesis into a sequence of events, providing a schematic view of the main components of adaptive and innate immunity in the liver and spleen after experimental infection with L. infantum or L. donovani. This review also presents several viewpoints and reflections about some controversial aspects of Leishmania research, including the choice of experimental model, route of administration, inoculum size and the relevance of pathology (intimately linked to parasite persistence): a thorough understanding of which is essential for future VL research and the successful development of efficient control strategies for Leishmania spp.
- Syrian Hamster
- Slc11a1 Gene
- Infected Macrophage
- Leishmania Parasite
- Hepatic Granuloma
Syrian hamster model of VL: suitability of this experimental model
Mouse model of VL: genetic control of susceptibility to L. infantum infection
- 4.BALB/c mouse model of VL: organ-specific immune responses
- 4.1.Liver: control of hepatic infection
Development of an immune response to the early stage of infection
Development of an immune response to the later stage of infection: granuloma formation
- 4.2.Spleen: L. infantum parasites persist and destroy the splenic architecture
The acute phase of infection
The chronic phase of infection
Pathological changes in the spleen
Remarks and discussion
The parasitic protozoa of the genus Leishmania cause a spectrum of diseases in humans, ranging from subclinical cutaneous infections to more serious disseminating diffuse cutaneous, mucocutaneous and visceral forms of the disease. Leishmaniosis is one of the most prevalent neglected tropical diseases affecting public health worldwide [1, 2]. It is transmitted by the bite of female sandflies. In developing countries it is associated with extreme poverty. It is estimated that at least 20 million people are infected with Leishmania. The visceral form is the most severe form of the disease. Annually, there are approximately 500 000 new cases of visceral leishmaniosis (VL) . Leishmania donovani is the primary cause of VL in the Indian subcontinent and East Africa, L. infantum in the areas surrounding the Mediterranean Sea where it is a zoonosis, and L. chagasi in the New World. The last two species are identical. Human beings are the only known reservoir of L. donovani, while canines provide the reservoir for L. infantum and L. chagasi. However, since asymptomatic parasitemic injecting drug users who share injecting devices seem to be a suitable reservoir for L infantum, an artificial anthro-ponotic cycle would be completed. Needles and syringes would be the vectors and uninfected injecting drug users the receptors . Also, L. infantum is known to cause opportunistic infections in patients with HIV/AIDS . Canis familiaris is the major host for these parasites, and the main reservoir for human visceral infection . The risk for reintroduction of VL and other vector-borne diseases in Europe as a consequence of global warming has recently been highlighted . Indeed, VL appears not to be limited to the Mediterranean region and has now spread northwards .
Manifestations of VL can vary from asymptomatic infection to progressive fatal visceral disease. Disease progression is dependent on both the species of Leishmania involved and the genetics and immune status of the host. Active VL is characterized by fever, weight loss, hypergammaglobulinemia, hepatosplenomegaly, anemia, thrombocytopenia, leukopenia and immunodepression [10, 11]. Also, the presence of parasite-specific antibodies forming immune complexes in the kidneys may lead to the development of glomerulonephritis [12, 13].
Leishmaniosis diagnosis and treatment are expensive. Despite considerable advances, there are still no efficient vaccines available against human leishmaniosis [14, 15]. Recently, a vaccine containing the fucose-mannose ligand has been industrialized and licensed for commercialization in Brazilian endemic areas under the name of Leishmune® (Fort Dodge Ltda, São Paulo, Brazil) to prevent canine VL. Unfortunately, the immune response induced by vaccination has not yet been fully investigated. Also, this vaccine is solely recommended for asymptomatic and seronegative dogs [16–19].
Several experimental models of VL have been developed, but none of these entirely reproduce the disease in humans . Much of the literature from these models documents the immune parameters contributing to resistance against the visceralizing Leishmania species used in vaccine studies . This contrasts with a limited number of studies which have been prompted to study pathological aspects related to VL. In this context, close attention should be given to the histopathological alterations. Humans, dogs and hamsters often exhibit severe clinical signs and symptoms during visceral infection [23–25], whereas mice generally show a few minor signs or no clinical signs at all, depending mainly on the size of the parasite inoculum . Under experimental conditions, progression of visceral disease also depends on the route of infection together with the strain of Leishmania parasites used . These factors make the choice of a suitable laboratory model difficult. Studies using experimental murine models of VL do not allow exact extrapolations to be made concerning susceptibility in dogs and humans, but increase the ease of identifying genes and predicting their functional roles, as well as investigating the immune mechanisms involved in human and canine leishmaniosis. This review will aim to provide a better understanding of a variety of pathological-immune responses that have been described to date in the most widely used experimental models of VL (Syrian hamsters and BALB/c mice). Combining research approaches at the immunological, pathological and genetic levels helps to advance our understanding of the mechanisms involved in visceral infection at different stages of the disease.
The usual routes of infection in the hamster model of VL are intracardiac and intraperitoneal. However, the administration of parasites by the saphenous vein in order to minimize stress on the hamsters has also been reported . Experimental studies in L. infantum and L. donovani-infected Syrian hamsters (Mesocricetus auratus) often reveal several clinical signs of progressive VL (hypergammaglobulinemia, hepatosplenomegaly, anemia, cachexia and immunodepression) that closely mimic active canine and human disease [22, 23, 25, 28, 29]. Surprisingly, there are significant amounts of Th1 cytokines (IFN-γ, IL-2 and TNF-α) in the spleen, but there is little or no IL-4. However, to allow the parasites to multiply, deactivating Th2 cytokines (TGF-β and IL-10) may act on infected macrophages as well as anti-Leishmania antibodies (which have no protective role in leishmaniosis) that opsonize amastigotes and induce IL-10 production in macrophages. These high activation and deactivation processes are likely to occur mainly in the spleen and liver . Interestingly, Syrian hamsters exhibit reduced expression of the gene encoding inducible nitric oxide synthase (iNOS) in response to IFN-γ, and this is thought to lead to a low nitric oxide (NO) generation, subsequently defaulting in parasite killing [10, 28, 31]. Furthermore, there is a lack of reagents for immunological analysis in the hamster model of VL. Taking these factors into account, we consider the Syrian hamster to be a suitable experimental model for the study of the pathological features of active VL (as described below), but it is not a suitable model for the evaluation of immunization strategies, as a result of the animal's high innate susceptibility.
In Syrian hamsters, manifestations of VL can range from asymptomatic and oligosymptomatic infections to progressive fatal visceral disease . The pathological features reported during VL include hypoplasia of the white pulp in the spleen, hepatic granulomas and the deposition of a secondary amyloid substance both in the spleen and the liver [32, 33]. Also, other studies of active VL have reported that infected hamsters develop glomerulonephritis associated with deposition of immunoglobulins and parasite antigens (immune complexes) in the kidneys. Finally, the disseminated amyloidosis and glomerulonephritis produce renal failure and nephrotic syndrome in infected hamsters [12, 34]. The visceral infection in hamsters also induces pathological alterations in hepatocytes, mainly in the endomembrane system and the peroxisomal compartment, leading to a disturbance of liver metabolism . In a recent study , hamsters infected with L. infantum were shown to develop analogous inflammatory myopathies to those observed in naturally infected dogs . Taken together, all these factors probably contributed to the immune response disorders that resulted in the death of the animals [22, 33].
Genes that control the immune response to L. donovani/L. infantum infection.
Host defense mechanism(s)
Locus or gene
Innate intraphagosomal control of infection in the spleen and the liver
Influences antigen presentation during the acquired immune response in the splen, the liver and the bone marrow
Formation of hepatic granulomas. Acquired immune response
Influences resistance to parasites in the spleen. C57BL/6J bg/bg mice expressed deficient natural killer cell activity and failed to eliminate L. donovani amastigotes
The parasite load in the liver at later stages of infection, which probably reflects the strength of the acquired immune response, was found to be controlled by the H2 and Ir2 loci. The haplotype at the H2 genomic region on chromosome 17 is involved in antigen presentation through the major histocompatibility complex (MHC). Genetic polymorphism in the MHC influences the response to numerous antigens. Several MHC haplotypes have not only been associated with resistance to leishmaniosis, but also with resistance to many other infections . Differences between the H-2 b and H-2 d haplotypes were observed in the BALB/c background, where H-2 b resulted in lower parasite numbers in the liver than H-2 d . In addition to the liver, the H2 region influences parasite numbers in the spleen and bone marrow . Histopathological analysis revealed that the Ir2 locus in mice promoted fewer granulomas that were smaller in size, due to an efficient anti-parasite response.
The parasite burden in the spleen was also found to be controlled by the Lyst/Beige gene on chromosome 13. Indeed, homozygous C57BL/6J bg/bg (beige) mice expressed deficient natural killer (NK) cell activity and failed to eliminate L. donovani amastigotes .
4.1. Liver: control of hepatic infection
4.1.1. Development of an immune response to the early stage of infection
After being inoculated into the lateral vein of the tail, the parasites enter the liver via the portal vein and invade macrophages and DCs. In both these types of host cell, promastigotes transform into amastigotes. At this point, the innate immune system constitutes its first line of defence against Leishmania parasites. The parasitized resident macrophages (Kupffer cells, KCs) secrete chemokines (CCL3, CCL2 and CXCL10) that stimulate the recruitment of monocytes and granulocytes . Despite the activation of these mechanisms in mice, amastigotes survive during the hepatic acute phase (up to two weeks post-infection (pi)) in an environment with small quantities of inflammatory cytokines, in the absence of activated T cells. Consequently, the number of parasites in the liver reaches a peak (Figure 4A). Nevertheless, the parasite burden may decrease dramatically with the acquisition of the granulomatous response during the next stage of infection, as described below.
4.1.2. Development of an immune response to the later stage of infection: granuloma formation
Recent research favours a model in which Leishmania-specific T lymphocytes are pre-activated in the spleen and then migrate to the liver . Once there, activated T cells interact with parasitized DCs, serving as a critical source of IL-12 production, that then triggers the subsequent Leishmania-specific CD4+ Th1 effector response during the later stage of infection . Interestingly, activated DCs can also trigger NK cell cytotoxicity and the production of IFN-γ . In contrast to DCs, the production of IL-12 is blocked in infected macrophages. Consequently, the parasite-carrying macrophages are incompetent at priming CD4+ T cells or stimulating antigen-specific CD4+ T cells . Therefore, the interaction of Leishmania-specific CD4+ T cells with infected DCs in the liver provides the proinflammatory (Th1) environment required for efficient granuloma formation (Figure 4B), which includes IL-12, IFN-γ, TNF-α and IL-2 production [10, 48, 51–53]. It is at this stage of infection (weeks 2-4 pi) that the acquired hepatic immune response is initiated. Simultaneously, the fusion of infected KCs to form multinucleated cells also contributes to inflammatory cytokine production during granuloma formation [54, 55]. In BALB/c mice, acquired hepatic resistance to L. infantum clearly depends upon granuloma development. Thus, the structure of a mature tissue granuloma consists of a core of fused, parasitized KCs with an encircling mononuclear cell mantle containing blood monocytes and both CD4+ and CD8+ T cells. In some instances, B cells, plasma cells and granulocytes are also attracted. In immunologically active granulomas, antigen-presenting DCs and cytokine-secreting T cells are required for antimicrobial activity . The formation of a granuloma is not always associated with parasite control, and the effectiveness of hepatic granulomas to kill parasites depends on their degree of maturation [52, 54]. It appears that the TNF family of cytokines are not involved in the formation of granulomas but instead are involved in their maturation, as well as the maintenance of splenic architecture .
Granulomas become fully evolved by 2-4 weeks pi. The overall antimicrobial efficacy of the granulomatous response appears to be variable, and only mature granulomas develop efficient leishmanicidal mechanisms to kill parasites. In contrast, developing granulomas have been reported to be less efficient at killing Leishmania parasites. Among other factors, granuloma development has been found to vary depending on the initial inoculum size. Indeed, higher numbers of mature and sterile granulomas are observed in mice infected with a low-inoculum size than in those infected with a high-inoculum size . In structurally mature hepatic granulomas, the elaboration of leishmanicidal reactive oxygen intermediates (ROIs) and reactive nitrogen intermediates (RNIs) is essential for parasite killing within infected KCs and DCs [44, 54].
There are various classification schemes for granulomatous inflammation in VL. Murray et al.  reported a summary of liver granuloma structure-function relationships in experimental VL. To score the progression of the granulomatous response, Stager et al.  also classified the infected focus as follows: (1) an infected KC with no associated cellular infiltrate, (2) an early granuloma comprising an infected KC surrounded by a few inflammatory cells, with no organization, (3) a mature granuloma with an organized structure, or (4) a sterile granuloma, in which amastigotes had been killed as a result of effective antileishmanial immunity. Following the above criteria our laboratory data also revealed that the resolution of disease in the livers of mice infected with L. infantum correlates with granuloma development (Figure 4C and Figure 5A). Early in the course of infection, granulomas at various stages of maturation are apparent . Thus, relatively mature granulomas can be readily detected alongside infected KCs that have no associated cellular infiltrate at around four weeks pi (Figure 4C). Infected KCs exhibiting no granulomatous reaction and immature granulomas (Figure 5B) were observed in high numbers at two weeks pi, but their numbers decreased during the course of infection as mature (Figure 5C), sterile (Figure 5D) granulomas developed, in which the amastigotes were killed. After eight weeks pi, sterile granulomas gradually dissembled in an involution process . Although sterile cure is never achieved in the liver, parasite growth is controlled without inducing pathology and it is resistant to secondary infections with L. infantum. It is possible that parasite persistence might mediate long-term immunity in the liver in a similar manner to that seen in the cutaneous leishmaniosis model caused by low-dose infection with L. major.
Studying the granulomatous response is important because granuloma development has been associated with Leishmania infection in the liver, as demonstrated in rodent models. Moreover, enhanced granuloma maturation represents a good marker of successful vaccination against VL .
4.2. Spleen: visceralizing Leishmania parasites persist and destroy the splenic architecture
In contrast to the liver, the spleen and bone marrow become chronically infected in mice . The immune response to L. infantum in the spleen (Figure 6A-C) can be separated into two phases: acute and chronic.
4.2.1. The acute phase of infection
Following intravenous experimental infection in mice, L. infantum promastigotes enter the spleen via the splenic artery and are rapidly removed from the circulation in the spleen by marginal zone (MZ) macrophages and rarely by DCs. It is likely that the majority of DCs acquire Leishmania antigens by phagocytosis of infected macrophages or their remnants in the MZ [44, 59]. Within these cells, promastigotes replicate intracellularly as amastigotes. In the spleen, MZ macrophages phagocytose > 95% of intravenously administered L. infantum parasites, where > 50% of the initial parasite inoculum is killed within 24 h of infection . It appears that DCs acquire parasite antigens within the MZ (Figure 6A) and subsequently migrate to the periarteriolar lymphoid sheath (PALS). Once in the PALS, DCs secrete IL-12  and present parasite antigens to T and NK cells, resulting in the activation of these effector cells (Figure 6B). Interestingly, L. infantum infection stimulates IL-12 production by splenic DCs within the PALS, but not infected macrophages within the MZ . As described above, evidence suggests that Leishmania-specific T lymphocytes are primed in the spleen during the acute stage of infection (< 4 weeks) and then migrate to the liver to initiate a granulomatous response [42, 44, 48, 62].
4.2.2. The chronic phase of infection
During the chronic stage of infection (> 4 weeks) in the spleen, failure to resolve L. infantum infection occurs (Figure 6C) and the splenic architecture breaks down. There are at least three possible explanations for the failure of the specific effector response : (1) assuming that the priming of T and NK cells by DCs occurs at the PALS, a site that is anatomically segregated from the MZ, infected macrophages fail to produce chemoattractants to bring effector cells into their vicinity. (2) Infected macrophages are unable to activate intrinsic leishmanicidal mechanisms following exposure to cytokines and ligands from T and NK cells. It has been reported that L. infantum-infected macrophages fail to produce IL-12 and also have a reduced capacity to generate both ROIs and NO, which are important microbicidal molecules for killing intracellular pathogens [44, 54, 61]. (3) Failure in the development of the efficient granulomatous immune effector response occurs in the spleen. Together, the low expression levels of MHC class II on L. infantum macrophages and their intrinsic defects in the generation of an antileishmanial response (see above), contribute to failure to form inflammatory foci around infected MZ macrophages .
Any of these three possibilities may contribute to the failure of the spleen to resolve murine VL. Paradoxically, the spleen is an initial site for the generation of cell-mediated immune responses, but ultimately becomes a site of parasite persistence, with associated immunopathological changes .
4.2.3. Pathological changes in the spleen
The experimental murine model of L. infantum infection mimics many of the features of canine and human infections. Syrian hamsters also exhibit severe clinical signs and symptoms that are similar to those observed in naturally infected dogs and humans [23, 24, 36]. However, the absence of iNOS expression [10, 28, 31] and the suppression of lymphoproliferative responses [64, 65] observed, lead us to argue that the hamster is a more suitable model for pathological studies of VL than for the evaluation of vaccine candidates. However, to date, most researchers have elected to use the BALB/c mouse model for investigating disease pathogenesis of VL, as well as for vaccine studies [26, 44, 54, 66–68]. In mice, the susceptibility to visceralizing Leishmania species is mainly determined by the Slc11a1 gene that encodes a phagosomal component that confers the ability to control the early infection (as described above). Even so, BALB/c mice, lacking this gene, are able to control the infection at a later stage [42, 69]. In this context, BALB/c mice provide a better model of self-healing or subclinical infection than of disseminated visceral disease . Paciello et al.  reported that susceptible mouse strains do not reproduce progressive disease as observed in human active VL. Furthermore, the intensity of pathological changes in the visceral organs of BALB/c mice can vary depending on the initial inoculum size, as described above. Indeed, we proposed that infecting mice with a large inoculum constitutes a suitable model for the study of the pathological changes of VL .
Infection with L. infantum, either intravenously or intradermally, leads to organ-specific immune responses that are important determinants of disease outcome in BALB/c mice [10, 48]. Apparently, the intravenous route of inoculation does not mimic natural infection by the sandfly . However, during natural infection, the blood-sucking action of the vector on the skin of the host may result in both intravenous and intradermal administration of the parasite . Subsequently, parasites multiply rapidly for the first few weeks in the liver. Curiously, the spleen is the initial site of generation of specific T effector cells with the ability to move to the liver. Once in the liver, the development of cell-mediated immune responses is essential for the clearance of L. infantum parasites. In contrast, the spleen ultimately becomes the site of parasite persistence [26, 44, 66, 70], suggesting that the spleen is more susceptible to L. infantum infection than the liver . Interestingly, the leishmanicidal efficacy of hepatic granulomas is dependent on their degree of maturation [26, 51, 56]. Therefore, determining the degree of maturation of hepatic granulomas constitutes an effective tool for selecting VL vaccine candidates and for monitoring disease progression.
In summary, it is reasonable to suppose that understanding the development of acquired parasite-specific immunity in the liver and the reasons for effector splenic response failure in VL, may lead to the development of effective strategies for parasite clearance in host target organs during VL and new treatments for canine and human leishmaniosis.
This research was support in part by a grant from the Spanish Ministry of Education and Science (MEC) (AGL2007-62207). Francisco Javier Carrión Herrero is an investigator of the "Juan de la Cierva" program (JCI-2009-04069) from the Spanish Ministry of Science and Innovation (MICINN).
- Murray HW, Berman JD, Davies CR, Saravia NG: Advances in leishmaniasis. Lancet. 2005, 366: 1561-1577. 10.1016/S0140-6736(05)67629-5.View ArticlePubMedGoogle Scholar
- Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, Savioli L: Control of neglected tropical diseases. N Engl J Med. 2007, 357: 1018-1027. 10.1056/NEJMra064142.View ArticlePubMedGoogle Scholar
- Hotez PJ: Nuclear weapons and neglected diseases: the "ten-thousand-to-one gap". PLoS Negl Trop Dis. 2010, 4: e680-10.1371/journal.pntd.0000680.PubMed CentralView ArticlePubMedGoogle Scholar
- Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD: Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002, 2: 494-501. 10.1016/S1473-3099(02)00347-X.View ArticlePubMedGoogle Scholar
- Pineda JA, Martin-Sanchez J, Macias J, Morillas F: Leishmania spp infection in injecting drug users. Lancet. 2002, 360: 950-951. 10.1016/S0140-6736(02)11056-7.View ArticlePubMedGoogle Scholar
- Dujardin JC, Campino L, Canavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M: Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg Infect Dis. 2008, 14: 1013-1018. 10.3201/eid1407.071589.PubMed CentralView ArticlePubMedGoogle Scholar
- Maia C, Nunes M, Cristovao J, Campino L: Experimental canine leishmaniasis: Clinical, parasitological and serological follow-up. Acta Trop. 2010, 116: 193-199. 10.1016/j.actatropica.2010.08.001.View ArticlePubMedGoogle Scholar
- Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, Genchi C, Gramiccia M, Mortarino M, Pietrobelli M, Gradoni L: The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop Med Int Health. 2008, 13: 256-264. 10.1111/j.1365-3156.2007.01998.x.View ArticlePubMedGoogle Scholar
- Bogdan C, Schonian G, Banuls AL, Hide M, Pratlong F, Lorenz E, Rollinghoff M, Mertens R: Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. Clin Infect Dis. 2001, 32: 302-306. 10.1086/318476.View ArticlePubMedGoogle Scholar
- Wilson ME, Jeronimo SM, Pearson RD: Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog. 2005, 38: 147-160. 10.1016/j.micpath.2004.11.002.View ArticlePubMedGoogle Scholar
- Pearson RD, Sousa AQ: Clinical spectrum of Leishmaniasis. Clin Infect Dis. 1996, 22: 1-13. 10.1093/clinids/22.Supplement_1.S1.View ArticlePubMedGoogle Scholar
- Sartori A, De Oliveira AV, Roque-Barreira MC, Rossi MA, Campos-Neto A: Immune complex glomerulonephritis in experimental kala-azar. Parasite Immunol. 1987, 9: 93-103. 10.1111/j.1365-3024.1987.tb00491.x.View ArticlePubMedGoogle Scholar
- Sanyal T, Ghosh DK, Sarkar D: Identification of immune complex antigens in sera of Indian kala-azar patients. Indian J Exp Biol. 1991, 29: 411-415.PubMedGoogle Scholar
- Croft SL, Vivas L, Brooker S: Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis. East Mediterr Health J. 2003, 9: 518-533.PubMedGoogle Scholar
- Choi CM, Lerner EA: Leishmaniasis as an emerging infection. J Investig Dermatol Symp Proc. 2001, 6: 175-182. 10.1046/j.0022-202x.2001.00038.x.View ArticlePubMedGoogle Scholar
- Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LO, de Oliveira Mendes-Aguiar C, de Souza EP, Fampa P, Parra LE, Menz I, Dias JG, de Oliveira SM, Palatnik-de-Sousa CB: The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine. 2006, 24: 2423-2431. 10.1016/j.vaccine.2005.11.061.View ArticlePubMedGoogle Scholar
- Parra LE, Borja-Cabrera GP, Santos FN, Souza LO, Palatnik-de-Sousa CB, Menz I: Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine. 2007, 25: 2180-2186. 10.1016/j.vaccine.2006.11.057.View ArticlePubMedGoogle Scholar
- Dantas-Torres F: Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol. 2006, 141: 1-8. 10.1016/j.vetpar.2006.05.001.View ArticlePubMedGoogle Scholar
- de Lima VM, Ikeda FA, Rossi CN, Feitosa MM, Vasconcelos RO, Nunes CM, Goto H: Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis. Vet Immunol Immunopathol. 2010, 135: 296-302. 10.1016/j.vetimm.2009.12.008.View ArticlePubMedGoogle Scholar
- Alexander J, Satoskar AR, Russell DG: Leishmania species: models of intracellular parasitism. J Cell Sci. 1999, 112 (Pt 18): 2993-3002.PubMedGoogle Scholar
- Antoine JC, Prina E, Courret N, Lang T: Leishmania spp.: on the interactions they establish with antigen-presenting cells of their mammalian hosts. Adv Parasitol. 2004, 58: 1-68. 10.1016/S0065-308X(04)58001-6.View ArticlePubMedGoogle Scholar
- Handman E: Leishmaniasis: current status of vaccine development. Clin Microbiol Rev. 2001, 14: 229-243. 10.1128/CMR.14.2.229-243.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Hommel M, Jaffe CL, Travi B, Milon G: Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann Trop Med Parasitol. 1995, 89 (Suppl 1): 55-73.PubMedGoogle Scholar
- Melby PC, Tabares A, Restrepo BI, Cardona AE, McGuff HS, Teale JM: Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection. Exp Parasitol. 2001, 99: 17-25. 10.1006/expr.2001.4640.View ArticlePubMedGoogle Scholar
- Requena JM, Soto M, Doria MD, Alonso C: Immune and clinical parameters associated with Leishmania infantum infection in the golden hamster model. Vet Immunol Immunopathol. 2000, 76: 269-281. 10.1016/S0165-2427(00)00221-X.View ArticlePubMedGoogle Scholar
- Carrion J, Nieto A, Iborra S, Iniesta V, Soto M, Folgueira C, Abanades DR, Requena JM, Alonso C: Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol. 2006, 28: 173-183. 10.1111/j.1365-3024.2006.00817.x.View ArticlePubMedGoogle Scholar
- Lei SM, Ramer-Tait AE, Dahlin-Laborde RR, Mullin K, Beetham JK: Reduced hamster usage and stress in propagating Leishmania chagasi promastigotes using cryopreservation and saphenous vein inoculation. J Parasitol. 2010, 96: 103-108. 10.1645/GE-2192.1.PubMed CentralView ArticlePubMedGoogle Scholar
- Melby PC, Chandrasekar B, Zhao W, Coe JE: The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol. 2001, 166: 1912-1920.View ArticlePubMedGoogle Scholar
- Dea-Ayuela MA, Rama-Iniguez S, Alunda JM, Bolas-Fernandez F: Setting new immunobiological parameters in the hamster model of visceral leishmaniasis for in vivo testing of antileishmanial compounds. Vet Res Commun. 2007, 31: 703-717. 10.1007/s11259-007-0040-5.View ArticlePubMedGoogle Scholar
- Goto H, Prianti MG: Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 2009, 51: 241-246.View ArticlePubMedGoogle Scholar
- Goto H, Lindoso JA: Immunity and immunosuppression in experimental visceral leishmaniasis. Braz J Med Biol Res. 2004, 37: 615-623. 10.1590/S0100-879X2004000400020.View ArticlePubMedGoogle Scholar
- Wilson ME, Innes DJ, Sousa AD, Pearson RD: Early histopathology of experimental infection with Leishmania donovani in hamsters. J Parasitol. 1987, 73: 55-63. 10.2307/3282344.View ArticlePubMedGoogle Scholar
- Rica-Capela MJ, Cortes S, Leandro C, Peleteiro MC, Santos-Gomes G, Campino L: Immunological and histopathological studies in a rodent model infected with Leishmania infantum promastigotes or amastigotes. Parasitol Res. 2003, 89: 163-169.PubMedGoogle Scholar
- Sartori A, Roque-Barreira MC, Coe J, Campos-Neto A: Immune complex glomerulonephritis in experimental kala-azar. II: Detection and characterization of parasite antigens and antibodies eluted from kidneys of Leishmania donovani-infected hamsters. Clin Exp Immunol. 1992, 87: 386-392. 10.1111/j.1365-2249.1992.tb03007.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Vianna VL, Takiya CM, de Brito-Gitirana L: Histopathologic analysis of hamster hepatocytes submitted to experimental infection with Leishmania donovani. Parasitol Res. 2002, 88: 829-836.View ArticlePubMedGoogle Scholar
- Paciello O, Wojcik S, Gradoni L, Oliva G, Trapani F, Iovane V, Politano L, Papparella S: Syrian hamster infected with Leishmania infantum: a new experimental model for inflammatory myopathies. Muscle Nerve. 2010, 41: 355-361. 10.1002/mus.21502.View ArticlePubMedGoogle Scholar
- Paciello O, Oliva G, Gradoni L, Manna L, Manzillo VF, Wojcik S, Trapani F, Papparella S: Canine inflammatory myopathy associated with Leishmania Infantum infection. Neuromuscul Disord. 2009, 19: 124-130. 10.1016/j.nmd.2008.10.013.View ArticlePubMedGoogle Scholar
- Nairz M, Fritsche G, Crouch ML, Barton HC, Fang FC, Weiss G: Slc11a1 limits intracellular growth of Salmonella enterica sv. Typhimurium by promoting macrophage immune effector functions and impairing bacterial iron acquisition. Cell Microbiol. 2009, 11: 1365-1381. 10.1111/j.1462-5822.2009.01337.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Roupie V, Rosseels V, Piersoel V, Zinniel DK, Barletta RG, Huygen K: Genetic resistance of mice to Mycobacterium paratuberculosis is influenced by Slc11a1 at the early but not at the late stage of infection. Infect Immun. 2008, 76: 2099-2105. 10.1128/IAI.01137-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Marquis JF, Gros P: Intracellular Leishmania: your iron or mine?. Trends Microbiol. 2007, 15: 93-95. 10.1016/j.tim.2007.01.001.View ArticlePubMedGoogle Scholar
- Huynh C, Andrews NW: Iron acquisition within host cells and the pathogenicity of Leishmania. Cell Microbiol. 2008, 10: 293-300. 10.1111/j.1462-5822.2007.01095.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, Zubairi S, Engwerda CR: The immunopathology of experimental visceral leishmaniasis. Immunol Rev. 2004, 201: 239-253. 10.1111/j.0105-2896.2004.00188.x.View ArticlePubMedGoogle Scholar
- Lipoldova M, Demant P: Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nat Rev Genet. 2006, 7: 294-305. 10.1038/nrg1832.View ArticlePubMedGoogle Scholar
- Stanley AC, Engwerda CR: Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol. 2007, 85: 138-147. 10.1038/sj.icb7100011.View ArticlePubMedGoogle Scholar
- Wegner KM, Kalbe M, Schaschl H, Reusch TB: Parasites and individual major histocompatibility complex diversity--an optimal choice?. Microbes Infect. 2004, 6: 1110-1116. 10.1016/j.micinf.2004.05.025.View ArticlePubMedGoogle Scholar
- Kirkpatrick CE, Farrell JP, Warner JF, Denner G: Participation of natural killer cells in the recovery of mice from visceral leishmaniasis. Cell Immunol. 1985, 92: 163-171. 10.1016/0008-8749(85)90074-7.View ArticlePubMedGoogle Scholar
- Bradley DJ, Kirkley J: Variation in susceptibility of mouse strains to Leishmania donovani infection. Trans R Soc Trop Med Hyg. 1972, 66: 527-528. 10.1016/0035-9203(72)90083-1.View ArticlePubMedGoogle Scholar
- Engwerda CR, Kaye PM: Organ-specific immune responses associated with infectious disease. Immunol Today. 2000, 21: 73-78. 10.1016/S0167-5699(99)01549-2.View ArticlePubMedGoogle Scholar
- Schleicher U, Liese J, Knippertz I, Kurzmann C, Hesse A, Heit A, Fischer JA, Weiss S, Kalinke U, Kunz S, Bogdan C: NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med. 2007, 204: 893-906. 10.1084/jem.20061293.PubMed CentralView ArticlePubMedGoogle Scholar
- Soong L: Modulation of dendritic cell function by Leishmania parasites. J Immunol. 2008, 180: 4355-4360.PubMed CentralView ArticlePubMedGoogle Scholar
- Murray HW, Squires KE, Miralles CD, Stoeckle MY, Granger AM, Granelli-Piperno A, Bogdan C: Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J Immunol. 1992, 148: 1858-1863.PubMedGoogle Scholar
- Murray HW, Nathan CF: Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med. 1999, 189: 741-746. 10.1084/jem.189.4.741.PubMed CentralView ArticlePubMedGoogle Scholar
- Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, Murray HW: Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol. 1989, 143: 4244-4249.PubMedGoogle Scholar
- Murray HW: Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol. 2001, 82: 249-267. 10.1046/j.1365-2613.2001.00199.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Hernandez-Pando R, Bornstein QL, Aguilar Leon D, Orozco EH, Madrigal VK, Martinez Cordero E: Inflammatory cytokine production by immunological and foreign body multinucleated giant cells. Immunology. 2000, 100: 352-358. 10.1046/j.1365-2567.2000.00025.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Stager S, Alexander J, Carter KC, Brombacher F, Kaye PM: Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun. 2003, 71: 4804-4807. 10.1128/IAI.71.8.4804-4807.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL: CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002, 420: 502-507. 10.1038/nature01152.View ArticlePubMedGoogle Scholar
- Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, McFarlane E: DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Vaccine. 2007, 25: 4502-4509. 10.1016/j.vaccine.2007.03.014.View ArticlePubMedGoogle Scholar
- Mebius RE, Kraal G: Structure and function of the spleen. Nat Rev Immunol. 2005, 5: 606-616. 10.1038/nri1669.View ArticlePubMedGoogle Scholar
- Ato M, Maroof A, Zubairi S, Nakano H, Kakiuchi T, Kaye PM: Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21. J Immunol. 2006, 176: 5486-5493.PubMed CentralView ArticlePubMedGoogle Scholar
- Gorak PM, Engwerda CR, Kaye PM: Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol. 1998, 28: 687-695. 10.1002/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0.CO;2-N.View ArticlePubMedGoogle Scholar
- Engwerda CR, Ato M, Kaye PM: Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol. 2004, 20: 524-530. 10.1016/j.pt.2004.08.009.View ArticlePubMedGoogle Scholar
- Smelt SC, Engwerda CR, McCrossen M, Kaye PM: Destruction of follicular dendritic cells during chronic visceral leishmaniasis. J Immunol. 1997, 158: 3813-3821.PubMedGoogle Scholar
- Dasgupta S, Mookerjee A, Chowdhury SK, Ghose AC: Immunosuppression in hamsters with progressive visceral leishmaniasis: an evaluation of the role of nitric oxide toward impairment of the lymphoproliferative response. Parasitol Res. 1999, 85: 594-596. 10.1007/s004360050600.View ArticlePubMedGoogle Scholar
- Mookerjee A, Sen PC, Ghose AC: Immunosuppression in hamsters with progressive visceral leishmaniasis is associated with an impairment of protein kinase C activity in their lymphocytes that can be partially reversed by okadaic acid or anti-transforming growth factor beta antibody. Infect Immun. 2003, 71: 2439-2446. 10.1128/IAI.71.5.2439-2446.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Ahmed S, Colmenares M, Soong L, Goldsmith-Pestana K, Munstermann L, Molina R, McMahon-Pratt D: Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun. 2003, 71: 401-410. 10.1128/IAI.71.1.401-410.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Carrion J, Folgueira C, Alonso C: Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine. 2008, 26: 2537-2544. 10.1016/j.vaccine.2008.03.003.View ArticlePubMedGoogle Scholar
- Ravindran R, Bhowmick S, Das A, Ali N: Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. BMC Microbiol. 2010, 10: 181-PubMed CentralView ArticlePubMedGoogle Scholar
- Mukherjee P, Ghosh AK, Ghose AC: Infection pattern and immune response in the spleen and liver of BALB/c mice intracardially infected with Leishmania donovani amastigotes. Immunol Lett. 2003, 86: 131-138. 10.1016/S0165-2478(03)00021-X.View ArticlePubMedGoogle Scholar
- Squires KE, Kirsch M, Silverstein SC, Acosta A, McElrath MJ, Murray HW: Defect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep mice. Infect Immun. 1990, 58: 3893-3898.PubMed CentralPubMedGoogle Scholar
- Rolao N, Cortes S, Gomes-Pereira S, Campino L: Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice. Exp Parasitol. 2007, 115: 270-276. 10.1016/j.exppara.2006.09.013.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.